-
1
-
-
33645526144
-
Cancer statistics
-
A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, and M.J. Thun Cancer statistics CA Cancer J. Clin. 56 2 2006 106 130
-
(2006)
CA Cancer J. Clin.
, vol.56
, Issue.2
, pp. 106-130
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Murray, T.4
Xu, J.5
Smigal, C.6
Thun, M.J.7
-
2
-
-
0345714860
-
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
-
A.A. Forastiere, H. Goepfert, M. Maor, T.F. Pajak, R. Weber, W. Morrison, B. Glisson, A. Trotti, J.A. Ridge, C. Chao, G. Peters, D.J. Lee, A. Leaf, J. Ensley, and J. Cooper Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N. Engl. J. Med. 349 22 2003 2091 2098
-
(2003)
N. Engl. J. Med.
, vol.349
, Issue.22
, pp. 2091-2098
-
-
Forastiere, A.A.1
Goepfert, H.2
Maor, M.3
Pajak, T.F.4
Weber, R.5
Morrison, W.6
Glisson, B.7
Trotti, A.8
Ridge, J.A.9
Chao, C.10
Peters, G.11
Lee, D.J.12
Leaf, A.13
Ensley, J.14
Cooper, J.15
-
3
-
-
0038387494
-
5-Fluorouracil: Mechanisms of action and clinical strategies
-
D.B. Longley, D.P. Harkin, and P.G. Johnston 5-Fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 3 5 2003 330 338
-
(2003)
Nat. Rev. Cancer
, vol.3
, Issue.5
, pp. 330-338
-
-
Longley, D.B.1
Harkin, D.P.2
Johnston, P.G.3
-
4
-
-
33847244929
-
Drug resistance, predictive markers and pharmacogenomics in colorectal cancer
-
D.B. Longley, W.L. Allen, and P.G. Johnston Drug resistance, predictive markers and pharmacogenomics in colorectal cancer Biochim. Biophys. Acta 1766 2 2006 184 196
-
(2006)
Biochim. Biophys. Acta
, vol.1766
, Issue.2
, pp. 184-196
-
-
Longley, D.B.1
Allen, W.L.2
Johnston, P.G.3
-
5
-
-
50949094432
-
5-Fluorouracil: Mechanisms of resistance and reversal strategies
-
N. Zhang, Y. Yin, S.J. Xu, and W.S. Chen 5-Fluorouracil: mechanisms of resistance and reversal strategies Molecules 13 8 2008 1551 1569
-
(2008)
Molecules
, vol.13
, Issue.8
, pp. 1551-1569
-
-
Zhang, N.1
Yin, Y.2
Xu, S.J.3
Chen, W.S.4
-
7
-
-
0002445885
-
Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas
-
Y. Shimosato, S. Oboshi, and K. Baba Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas Jpn. J. Clin. Oncol. 1 1 1971 19 35
-
(1971)
Jpn. J. Clin. Oncol.
, vol.1
, Issue.1
, pp. 19-35
-
-
Shimosato, Y.1
Oboshi, S.2
Baba, K.3
-
8
-
-
80054980154
-
Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma
-
M. Nagata, H. Nakayama, T. Tanaka, R. Yoshida, Y. Yoshitake, D. Fukuma, K. Kawahara, Y. Nakagawa, K. Ota, A. Hiraki, and M. Shinohara Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma Br. J. Cancer 105 9 2011 1322 1330
-
(2011)
Br. J. Cancer
, vol.105
, Issue.9
, pp. 1322-1330
-
-
Nagata, M.1
Nakayama, H.2
Tanaka, T.3
Yoshida, R.4
Yoshitake, Y.5
Fukuma, D.6
Kawahara, K.7
Nakagawa, Y.8
Ota, K.9
Hiraki, A.10
Shinohara, M.11
-
9
-
-
7044264360
-
Role of osteopontin in adhesion, migration, cell survival and bone remodeling
-
T. Standal, M. Borset, and A. Sundan Role of osteopontin in adhesion, migration, cell survival and bone remodeling Exp. Oncol. 26 3 2004 179 184
-
(2004)
Exp. Oncol.
, vol.26
, Issue.3
, pp. 179-184
-
-
Standal, T.1
Borset, M.2
Sundan, A.3
-
10
-
-
72949119124
-
Integrins in cancer: Biological implications and therapeutic opportunities
-
J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 1 2009 9 22
-
(2009)
Nat. Rev. Cancer
, vol.10
, Issue.1
, pp. 9-22
-
-
Desgrosellier, J.S.1
Cheresh, D.A.2
-
11
-
-
0029816589
-
5-Fluorouracil in colorectal cancer, a never ending story
-
R. Herrmann 5-Fluorouracil in colorectal cancer, a never ending story Ann. Oncol. 7 6 1996 551 552
-
(1996)
Ann. Oncol.
, vol.7
, Issue.6
, pp. 551-552
-
-
Herrmann, R.1
-
12
-
-
1642576129
-
Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays
-
H.C. Kang, I.J. Kim, J.H. Park, Y. Shin, J.L. Ku, M.S. Jung, B.C. Yoo, H.K. Kim, and J.G. Park Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays Clin. Cancer Res. 10 1 Pt. 1 2004 272 284
-
(2004)
Clin. Cancer Res.
, vol.10
, Issue.1
, pp. 272-284
-
-
Kang, H.C.1
Kim, I.J.2
Park, J.H.3
Shin, Y.4
Ku, J.L.5
Jung, M.S.6
Yoo, B.C.7
Kim, H.K.8
Park, J.G.9
-
13
-
-
3042631054
-
Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line
-
B.C. Yoo, E. Jeon, S.H. Hong, Y.K. Shin, H.J. Chang, and J.G. Park Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line Clin. Cancer Res. 10 12 Pt 1 2004 4176 4184
-
(2004)
Clin. Cancer Res.
, vol.10
, Issue.12
, pp. 4176-4184
-
-
Yoo, B.C.1
Jeon, E.2
Hong, S.H.3
Shin, Y.K.4
Chang, H.J.5
Park, J.G.6
-
14
-
-
8544224306
-
Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells
-
W. Wang, J. Cassidy, V. O'Brien, K.M. Ryan, and E. Collie-Duguid Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells Cancer Res. 64 22 2004 8167 8176
-
(2004)
Cancer Res.
, vol.64
, Issue.22
, pp. 8167-8176
-
-
Wang, W.1
Cassidy, J.2
O'Brien, V.3
Ryan, K.M.4
Collie-Duguid, E.5
-
15
-
-
77955376177
-
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression
-
S.L. Petersen, M. Peyton, J.D. Minna, and X. Wang Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression Proc. Natl. Acad. Sci. USA 107 26 2010 11936 11941
-
(2010)
Proc. Natl. Acad. Sci. USA
, vol.107
, Issue.26
, pp. 11936-11941
-
-
Petersen, S.L.1
Peyton, M.2
Minna, J.D.3
Wang, X.4
-
16
-
-
0030064334
-
Receptor-ligand interaction between CD44 and osteopontin (Eta-1)
-
G.F. Weber, S. Ashkar, M.J. Glimcher, and H. Cantor Receptor-ligand interaction between CD44 and osteopontin (Eta-1) Science 271 5248 1996 509 512
-
(1996)
Science
, vol.271
, Issue.5248
, pp. 509-512
-
-
Weber, G.F.1
Ashkar, S.2
Glimcher, M.J.3
Cantor, H.4
-
17
-
-
6344258588
-
The role of osteopontin in tumor metastasis
-
P.Y. Wai, and P.C. Kuo The role of osteopontin in tumor metastasis J. Surg. Res. 121 2 2004 228 241
-
(2004)
J. Surg. Res.
, vol.121
, Issue.2
, pp. 228-241
-
-
Wai, P.Y.1
Kuo, P.C.2
-
18
-
-
57049166456
-
Osteopontin: Role in immune regulation and stress responses
-
K.X. Wang, and D.T. Denhardt Osteopontin: role in immune regulation and stress responses Cytokine Growth Factor Rev. 19 5-6 2008 333 345
-
(2008)
Cytokine Growth Factor Rev.
, vol.19
, Issue.56
, pp. 333-345
-
-
Wang, K.X.1
Denhardt, D.T.2
-
19
-
-
0027131418
-
Osteopontin: A protein with diverse functions
-
D.T. Denhardt, and X. Guo Osteopontin: a protein with diverse functions FASEB J. 7 15 1993 1475 1482
-
(1993)
FASEB J.
, vol.7
, Issue.15
, pp. 1475-1482
-
-
Denhardt, D.T.1
Guo, X.2
-
20
-
-
0032432558
-
Osteopontin expression and function: Role in bone remodeling
-
D.T. Denhardt, and M. Noda Osteopontin expression and function: role in bone remodeling J. Cell. Biochem. 30-31 1998 92 102
-
(1998)
J. Cell. Biochem.
, vol.30-31
, pp. 92-102
-
-
Denhardt, D.T.1
Noda, M.2
-
21
-
-
35548995858
-
Osteopontin regulates hindlimb-unloading-induced lymphoid organ atrophy and weight loss by modulating corticosteroid production
-
K.X. Wang, Y. Shi, and D.T. Denhardt Osteopontin regulates hindlimb-unloading-induced lymphoid organ atrophy and weight loss by modulating corticosteroid production Proc. Natl. Acad. Sci. USA 104 37 2007 14777 14782
-
(2007)
Proc. Natl. Acad. Sci. USA
, vol.104
, Issue.37
, pp. 14777-14782
-
-
Wang, K.X.1
Shi, Y.2
Denhardt, D.T.3
-
22
-
-
0000022154
-
Altered wound healing in mice lacking a functional osteopontin gene (spp1)
-
L. Liaw, D.E. Birk, C.B. Ballas, J.S. Whitsitt, J.M. Davidson, and B.L. Hogan Altered wound healing in mice lacking a functional osteopontin gene (spp1) J. Clin. Invest. 101 7 1998 1468 1478
-
(1998)
J. Clin. Invest.
, vol.101
, Issue.7
, pp. 1468-1478
-
-
Liaw, L.1
Birk, D.E.2
Ballas, C.B.3
Whitsitt, J.S.4
Davidson, J.M.5
Hogan, B.L.6
-
23
-
-
85047690295
-
Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis
-
N. Yamamoto, F. Sakai, S. Kon, J. Morimoto, C. Kimura, H. Yamazaki, I. Okazaki, N. Seki, T. Fujii, and T. Uede Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis J. Clin. Invest. 112 2 2003 181 188
-
(2003)
J. Clin. Invest.
, vol.112
, Issue.2
, pp. 181-188
-
-
Yamamoto, N.1
Sakai, F.2
Kon, S.3
Morimoto, J.4
Kimura, C.5
Yamazaki, H.6
Okazaki, I.7
Seki, N.8
Fujii, T.9
Uede, T.10
-
24
-
-
0035941106
-
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
-
D. Chabas, S.E. Baranzini, D. Mitchell, C.C. Bernard, S.R. Rittling, D.T. Denhardt, R.A. Sobel, C. Lock, M. Karpuj, R. Pedotti, R. Heller, J.R. Oksenberg, and L. Steinman The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease Science 294 5547 2001 1731 1735
-
(2001)
Science
, vol.294
, Issue.5547
, pp. 1731-1735
-
-
Chabas, D.1
Baranzini, S.E.2
Mitchell, D.3
Bernard, C.C.4
Rittling, S.R.5
Denhardt, D.T.6
Sobel, R.A.7
Lock, C.8
Karpuj, M.9
Pedotti, R.10
Heller, R.11
Oksenberg, J.R.12
Steinman, L.13
-
25
-
-
2942511574
-
Role of osteopontin in tumor progression
-
S.R. Rittling, and A.F. Chambers Role of osteopontin in tumor progression Br. J. Cancer 90 10 2004 1877 1881
-
(2004)
Br. J. Cancer
, vol.90
, Issue.10
, pp. 1877-1881
-
-
Rittling, S.R.1
Chambers, A.F.2
-
26
-
-
77956442992
-
Osteopontin is a marker for cancer aggressiveness and patient survival
-
G.F. Weber, G.S. Lett, and N.C. Haubein Osteopontin is a marker for cancer aggressiveness and patient survival Br. J. Cancer 103 6 2010 861 869
-
(2010)
Br. J. Cancer
, vol.103
, Issue.6
, pp. 861-869
-
-
Weber, G.F.1
Lett, G.S.2
Haubein, N.C.3
-
27
-
-
78651376714
-
Categorical meta-analysis of osteopontin as a clinical cancer marker
-
G.F. Weber, G.S. Lett, and N.C. Haubein Categorical meta-analysis of osteopontin as a clinical cancer marker Oncol. Rep. 25 2 2011 433 441
-
(2011)
Oncol. Rep.
, vol.25
, Issue.2
, pp. 433-441
-
-
Weber, G.F.1
Lett, G.S.2
Haubein, N.C.3
-
28
-
-
84904410186
-
Osteopontin as a therapeutic target for cancer
-
M. Bandopadhyay, A. Bulbule, R. Butti, G. Chakraborty, P. Ghorpade, P. Ghosh, M. Gorain, S. Kale, D. Kumar, S. Kumar, K.V. Totakura, G. Roy, P. Sharma, D. Shetti, G. Soundararajan, D. Thorat, D. Tomar, R. Nalukurthi, R. Raja, R. Mishra, A.S. Yadav, and G.C. Kundu Osteopontin as a therapeutic target for cancer Expert Opin. Ther. Targets 18 8 2014 883 895
-
(2014)
Expert Opin. Ther. Targets
, vol.18
, Issue.8
, pp. 883-895
-
-
Bandopadhyay, M.1
Bulbule, A.2
Butti, R.3
Chakraborty, G.4
Ghorpade, P.5
Ghosh, P.6
Gorain, M.7
Kale, S.8
Kumar, D.9
Kumar, S.10
Totakura, K.V.11
Roy, G.12
Sharma, P.13
Shetti, D.14
Soundararajan, G.15
Thorat, D.16
Tomar, D.17
Nalukurthi, R.18
Raja, R.19
Mishra, R.20
Yadav, A.S.21
Kundu, G.C.22
more..
-
29
-
-
34247346481
-
Plasma osteopontin is an independent prognostic marker for head and neck cancers
-
D. Petrik, P.W. Lavori, H. Cao, Y. Zhu, P. Wong, E. Christofferson, M.J. Kaplan, H.A. Pinto, P. Sutphin, A.C. Koong, A.J. Giaccia, and Q.T. Le Plasma osteopontin is an independent prognostic marker for head and neck cancers J. Clin. Oncol. 24 33 2006 5291 5297
-
(2006)
J. Clin. Oncol.
, vol.24
, Issue.33
, pp. 5291-5297
-
-
Petrik, D.1
Lavori, P.W.2
Cao, H.3
Zhu, Y.4
Wong, P.5
Christofferson, E.6
Kaplan, M.J.7
Pinto, H.A.8
Sutphin, P.9
Koong, A.C.10
Giaccia, A.J.11
Le, Q.T.12
-
30
-
-
12244267969
-
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas
-
Q.T. Le, P.D. Sutphin, S. Raychaudhuri, S.C. Yu, D.J. Terris, H.S. Lin, B. Lum, H.A. Pinto, A.C. Koong, and A.J. Giaccia Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas Clin. Cancer Res. 9 1 2003 59 67
-
(2003)
Clin. Cancer Res.
, vol.9
, Issue.1
, pp. 59-67
-
-
Le, Q.T.1
Sutphin, P.D.2
Raychaudhuri, S.3
Yu, S.C.4
Terris, D.J.5
Lin, H.S.6
Lum, B.7
Pinto, H.A.8
Koong, A.C.9
Giaccia, A.J.10
-
31
-
-
84883539709
-
Osteopontin expression is an independent factor for poor survival in oral squamous cell carcinoma: A computer-assisted analysis on TMA sections
-
M. Avirović, K. Matušan-Ilijaš, G. Damante, D. Fabrro, R. Cerović, M. Juretić, B. Grahovac, N. Jonjić, and K. Lučin Osteopontin expression is an independent factor for poor survival in oral squamous cell carcinoma: a computer-assisted analysis on TMA sections J. Oral Pathol. Med. 42 8 2013 620 626
-
(2013)
J. Oral Pathol. Med.
, vol.42
, Issue.8
, pp. 620-626
-
-
Avirović, M.1
Matušan-Ilijaš, K.2
Damante, G.3
Fabrro, D.4
Cerović, R.5
Juretić, M.6
Grahovac, B.7
Jonjić, N.8
Lučin, K.9
-
32
-
-
84898835302
-
Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma
-
M. Mardani, A. Andisheh-Tadbir, B. Khademi, M.J. Fattahi, S. Shafiee, and M. Asad-Zadeh Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma Tumor Biol. 35 4 2014 3827 3829
-
(2014)
Tumor Biol.
, vol.35
, Issue.4
, pp. 3827-3829
-
-
Mardani, M.1
Andisheh-Tadbir, A.2
Khademi, B.3
Fattahi, M.J.4
Shafiee, S.5
Asad-Zadeh, M.6
-
33
-
-
26444467146
-
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial
-
Danish Head And Neck Cancer Study Group
-
J. Overgaard, J.G. Eriksen, M. Nordsmark, J. Alsner, M.R. Horsman, and Danish Head and Neck Cancer Study Group Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial Lancet Oncol. 6 10 2005 757 764
-
(2005)
Lancet Oncol.
, vol.6
, Issue.10
, pp. 757-764
-
-
Overgaard, J.1
Eriksen, J.G.2
Nordsmark, M.3
Alsner, J.4
Horsman, M.R.5
-
34
-
-
26444466467
-
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study
-
M. Nordsmark, S.M. Bentzen, V. Rudat, D. Brizel, E. Lartigau, P. Stadler, A. Becker, M. Adam, M. Molls, J. Dunst, D.J. Terris, and J. Overgaard Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study Radiother. Oncol. 77 1 2005 18 24
-
(2005)
Radiother. Oncol.
, vol.77
, Issue.1
, pp. 18-24
-
-
Nordsmark, M.1
Bentzen, S.M.2
Rudat, V.3
Brizel, D.4
Lartigau, E.5
Stadler, P.6
Becker, A.7
Adam, M.8
Molls, M.9
Dunst, J.10
Terris, D.J.11
Overgaard, J.12
-
35
-
-
33748034069
-
Molecular responses of rectal cancer to preoperative chemoradiation
-
A. Debucquoy, L. Goethals, K. Geboes, S. Roels, W.H. Mc Bride, and K. Haustermans Molecular responses of rectal cancer to preoperative chemoradiation Radiother. Oncol. 80 2 2006 172 177
-
(2006)
Radiother. Oncol.
, vol.80
, Issue.2
, pp. 172-177
-
-
Debucquoy, A.1
Goethals, L.2
Geboes, K.3
Roels, S.4
Mc Bride, W.H.5
Haustermans, K.6
-
36
-
-
58149216787
-
Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer
-
E.P. Hui, F.L. Sung, B.K. Yu, C.S. Wong, B.B. Ma, X. Lin, A. Chan, W.L. Wong, and A.T. Chan Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer Clin. Cancer Res. 14 21 2008 7080 7087
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.21
, pp. 7080-7087
-
-
Hui, E.P.1
Sung, F.L.2
Yu, B.K.3
Wong, C.S.4
Ma, B.B.5
Lin, X.6
Chan, A.7
Wong, W.L.8
Chan, A.T.9
-
37
-
-
26944478634
-
Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer
-
Y. Zhu, D.T. Denhardt, H. Cao, P.D. Sutphin, A.C. Koong, A.J. Giaccia, and Q.T. Le Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer Oncogene 24 43 2005 6555 6563
-
(2005)
Oncogene
, vol.24
, Issue.43
, pp. 6555-6563
-
-
Zhu, Y.1
Denhardt, D.T.2
Cao, H.3
Sutphin, P.D.4
Koong, A.C.5
Giaccia, A.J.6
Le, Q.T.7
-
38
-
-
33751162608
-
Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels
-
M. Bache, R. Reddemann, H.M. Said, H.J. Holzhausen, H. Taubert, A. Becker, T. Kuhnt, G. Hänsgen, J. Dunst, and D. Vordermark Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels Int. J. Radiat. Oncol. Biol. Phys. 66 5 2006 1481 1487
-
(2006)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.66
, Issue.5
, pp. 1481-1487
-
-
Bache, M.1
Reddemann, R.2
Said, H.M.3
Holzhausen, H.J.4
Taubert, H.5
Becker, A.6
Kuhnt, T.7
Hänsgen, G.8
Dunst, J.9
Vordermark, D.10
-
39
-
-
84876544010
-
Upregulation of drug transporter expression by osteopontin in prostate cancer cells
-
I.S. Hsieh, W.H. Huang, H.C. Liou, W.J. Chuang, R.S. Yang, and W.M. Fu Upregulation of drug transporter expression by osteopontin in prostate cancer cells Mol. Pharmacol. 83 5 2013 968 977
-
(2013)
Mol. Pharmacol.
, vol.83
, Issue.5
, pp. 968-977
-
-
Hsieh, I.S.1
Huang, W.H.2
Liou, H.C.3
Chuang, W.J.4
Yang, R.S.5
Fu, W.M.6
-
40
-
-
0031596991
-
NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival
-
M. Scatena, M. Almeida, M.L. Chaisson, N. Fausto, R.F. Nicosia, and C.M. Giachelli NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival J. Cell Biol. 141 4 1998 1083 1093
-
(1998)
J. Cell Biol.
, vol.141
, Issue.4
, pp. 1083-1093
-
-
Scatena, M.1
Almeida, M.2
Chaisson, M.L.3
Fausto, N.4
Nicosia, R.F.5
Giachelli, C.M.6
-
41
-
-
58749094152
-
Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells
-
G. Song, Y. Ming, Y. Mao, S. Bao, and G. Ouyang Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells Exp. Biol. Med. (Maywood) 233 12 2008 1537 1545
-
(2008)
Exp. Biol. Med. (Maywood)
, vol.233
, Issue.12
, pp. 1537-1545
-
-
Song, G.1
Ming, Y.2
Mao, Y.3
Bao, S.4
Ouyang, G.5
-
42
-
-
0033929141
-
Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met)
-
A.B. Tuck, B.E. Elliott, C. Hota, E. Tremblay, and A.F. Chambers Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met) J. Cell. Biochem. 78 3 2000 465 475
-
(2000)
J. Cell. Biochem.
, vol.78
, Issue.3
, pp. 465-475
-
-
Tuck, A.B.1
Elliott, B.E.2
Hota, C.3
Tremblay, E.4
Chambers, A.F.5
-
43
-
-
44649088833
-
Systemic endocrine instigation of indolent tumor growth requires osteopontin
-
S. Sandra, S.S. McAllister, A.M. Gifford, A.L. Greiner, S.P. Kelleher, M.P. Saelzler, T.A. Ince, F. Reinhardt, L.N. Harris, B.L. Hylander, E.A. Repasky, and R.A. Weinberg Systemic endocrine instigation of indolent tumor growth requires osteopontin Cell 133 6 2008 994 1005
-
(2008)
Cell
, vol.133
, Issue.6
, pp. 994-1005
-
-
Sandra, S.1
McAllister, S.S.2
Gifford, A.M.3
Greiner, A.L.4
Kelleher, S.P.5
Saelzler, M.P.6
Ince, T.A.7
Reinhardt, F.8
Harris, L.N.9
Hylander, B.L.10
Repasky, E.A.11
Weinberg, R.A.12
-
44
-
-
38149098569
-
Phase i and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against avb3 integrin receptor, in patients with advanced solid tumors
-
C. Delbaldo, E. Raymond, K. Vera, L. Hammershaimb, K. Kaucic, S. Lozahic, M. Marty, and S. Faivre Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against avb3 integrin receptor, in patients with advanced solid tumors Invest. New Drugs 26 1 2008 35 43
-
(2008)
Invest. New Drugs
, vol.26
, Issue.1
, pp. 35-43
-
-
Delbaldo, C.1
Raymond, E.2
Vera, K.3
Hammershaimb, L.4
Kaucic, K.5
Lozahic, S.6
Marty, M.7
Faivre, S.8
-
45
-
-
77949394260
-
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin avb3 ± dacarbazine in patients with stage IV metastatic melanoma
-
P. Hersey, J. Sosman, S. O'Day, J. Richards, A. Bedikian, R. Gonzalez, W. Sharfman, R. Weber, T. Logan, M. Buzoianu, L. Hammershaimb, J.M. Kirkwood, and Etaracizumab Melanoma Study Group A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin avb3 ± dacarbazine in patients with stage IV metastatic melanoma Cancer 116 6 2010 1526 1534
-
(2010)
Cancer
, vol.116
, Issue.6
, pp. 1526-1534
-
-
Hersey, P.1
Sosman, J.2
O'Day, S.3
Richards, J.4
Bedikian, A.5
Gonzalez, R.6
Sharfman, W.7
Weber, R.8
Logan, T.9
Buzoianu, M.10
Hammershaimb, L.11
Kirkwood, J.M.12
-
46
-
-
55849128163
-
Tumor-selective response to antibody-mediated targeting of avb3integrin in ovarian cancer
-
C.N. Landen, T.J. Kim, Y.G. Lin, W.M. Merritt, A.A. Kamat, L.Y. Han, W.A. Spannuth, A.M. Nick, N.B. Jennnings, M.S. Kinch, D. Tice, and A.K. Sood Tumor-selective response to antibody-mediated targeting of avb3integrin in ovarian cancer Neoplasia 10 11 2008 1259 1267
-
(2008)
Neoplasia
, vol.10
, Issue.11
, pp. 1259-1267
-
-
Landen, C.N.1
Kim, T.J.2
Lin, Y.G.3
Merritt, W.M.4
Kamat, A.A.5
Han, L.Y.6
Spannuth, W.A.7
Nick, A.M.8
Jennnings, N.B.9
Kinch, M.S.10
Tice, D.11
Sood, A.K.12
-
47
-
-
77954941784
-
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma
-
S.J. Moschos, C.A. Sander, W. Wang, S.L. Reppert, L.M. Drogowski, D.M. Jukic, U.N. Rao, C. Athanassiou, M. Buzoianu, M. Mandic, L. Richman, L. McKinney, J. Leininger, D.A. Tice, L. Hammershaimb, and J.M. Kirkwood Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma J. Immunother. 33 3 2010 316 325
-
(2010)
J. Immunother.
, vol.33
, Issue.3
, pp. 316-325
-
-
Moschos, S.J.1
Sander, C.A.2
Wang, W.3
Reppert, S.L.4
Drogowski, L.M.5
Jukic, D.M.6
Rao, U.N.7
Athanassiou, C.8
Buzoianu, M.9
Mandic, M.10
Richman, L.11
McKinney, L.12
Leininger, J.13
Tice, D.A.14
Hammershaimb, L.15
Kirkwood, J.M.16
-
48
-
-
79957671402
-
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: Findings of the phase i part
-
J.B. Vermorken, J. Guigay, R. Mesia, J.M. Trigo, U. Keilholz, A. Kerber, U. Bethe, M. Picard, and T.H. Brummendorf Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part Br. J. Cancer 104 11 2011 1691 1696
-
(2011)
Br. J. Cancer
, vol.104
, Issue.11
, pp. 1691-1696
-
-
Vermorken, J.B.1
Guigay, J.2
Mesia, R.3
Trigo, J.M.4
Keilholz, U.5
Kerber, A.6
Bethe, U.7
Picard, M.8
Brummendorf, T.H.9
|